MX2010009576A - Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes. - Google Patents

Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes.

Info

Publication number
MX2010009576A
MX2010009576A MX2010009576A MX2010009576A MX2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A MX 2010009576 A MX2010009576 A MX 2010009576A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
insulin secretion
obtaining
methods
Prior art date
Application number
MX2010009576A
Other languages
Spanish (es)
Inventor
Micheline Kergoat
Gerard Botton
Samer Elbawab
Christine Charon
Eric Valerur
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2010009576A publication Critical patent/MX2010009576A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The present invention relates to quinoxalinone derivatives of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these quinoxalinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated. Other preferred compounds are compounds of general formula (I), wherein R1, R2, R3, R4, R5 and R6 can be optionally substituted by one or more groups selected from Z.
MX2010009576A 2008-03-05 2009-01-15 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes. MX2010009576A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004053 2008-03-05
PCT/EP2009/000209 WO2009109258A1 (en) 2008-03-05 2009-01-15 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (1)

Publication Number Publication Date
MX2010009576A true MX2010009576A (en) 2010-09-24

Family

ID=40547943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009576A MX2010009576A (en) 2008-03-05 2009-01-15 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes.

Country Status (18)

Country Link
US (2) US8415352B2 (en)
EP (1) EP2247580B1 (en)
JP (1) JP5618837B2 (en)
KR (1) KR101637387B1 (en)
CN (1) CN101952258B (en)
AR (1) AR070797A1 (en)
AU (1) AU2009221327B2 (en)
BR (1) BRPI0908406B8 (en)
CA (1) CA2717718C (en)
DK (1) DK2247580T3 (en)
EA (1) EA021904B1 (en)
ES (1) ES2548583T3 (en)
HU (1) HUE027811T2 (en)
IL (1) IL207720A (en)
MX (1) MX2010009576A (en)
PT (1) PT2247580E (en)
WO (1) WO2009109258A1 (en)
ZA (1) ZA201007059B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2841428T (en) 2012-04-24 2018-11-29 Vertex Pharma Dna-pk inhibitors
DK3527563T3 (en) 2013-03-12 2021-12-06 Vertex Pharma DNA-PK INHIBITORS
SG11201602962PA (en) 2013-10-17 2016-05-30 Vertex Pharma Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
CN104628661A (en) * 2015-02-05 2015-05-20 北京理工大学 Structure of quinoxalinone derivatives as aldose reductase inhibitor, preparation method and use
CA3009531A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California 5-substituted [1,3,4]thiadiazol-2-amido derivatives and use as cftr reg ulators
CA3009534A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of California 3-aryl-quinoxalinone derivatives and use thereof as cftr regulators
PL3394040T3 (en) 2015-12-24 2022-05-02 The Regents Of The University Of California Cftr regulators and methods of use thereof
CN105769870A (en) * 2016-04-09 2016-07-20 李曼 Drug for treating diabetes
MX2019003317A (en) 2016-09-27 2019-08-05 Vertex Pharma Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors.
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
CN109796417A (en) * 2019-01-14 2019-05-24 北京理工大学 A series of structure of quinokysalines derivatives, Preparation method and use
CN109793739A (en) * 2019-01-14 2019-05-24 北京理工大学 A kind of structure of quinokysalines derivative, Preparation method and use
CN114907323B (en) * 2022-05-31 2023-08-15 内蒙古民族大学 Quinoxalinone compounds, preparation method and application thereof
CN114957222B (en) * 2022-05-31 2023-08-15 内蒙古民族大学 Compound and preparation method and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU410015A1 (en) * 1971-06-22 1974-01-05
SU616955A1 (en) * 1977-03-02 2006-12-27 Пермский ордена Трудового Красного Знамени государственный университет им.А.М.Горького 2- (α-bromfenacil) -quinoxalon-3, showing anti-inflammatory activity
US4181724A (en) 1978-09-11 1980-01-01 The Upjohn Company Quinoxalinone compounds useful for expanding the lumina or air passages in mammals
FR2653430B1 (en) * 1989-10-23 1991-12-20 Pf Medicament NEW DIHYDRO-1,2 OXO-2 QUINOXALINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
CA2295239A1 (en) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
NZ503076A (en) * 1997-09-01 2002-10-25 Kyorin Seiyaku Kk 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives and addition salts thereof, with antagonism against amino acid receptors (particularly AMPA receptor) and processes for their preparation
CA2319554C (en) 1998-03-31 2005-06-28 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
DE10343098A1 (en) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydroquinoxalines and their use
ATE367161T1 (en) * 2004-01-06 2007-08-15 Janssen Pharmaceutica Nv (3-OXO-3,4-DIHYDRO-QUINOXALINE-2-YL-AMINO)- BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY
DE102004023332A1 (en) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Quinoxaline-2-one derivatives, crop protection agents containing them, and processes for their preparation and their use
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds

Also Published As

Publication number Publication date
CA2717718C (en) 2016-05-31
BRPI0908406B8 (en) 2023-02-07
CN101952258B (en) 2014-03-19
US8415352B2 (en) 2013-04-09
ZA201007059B (en) 2011-06-29
DK2247580T3 (en) 2015-10-05
US8835634B2 (en) 2014-09-16
ES2548583T3 (en) 2015-10-19
AU2009221327A1 (en) 2009-09-11
EP2247580B1 (en) 2015-07-08
US20110015194A1 (en) 2011-01-20
JP5618837B2 (en) 2014-11-05
JP2011513343A (en) 2011-04-28
PT2247580E (en) 2015-10-19
BRPI0908406A2 (en) 2015-08-11
EA201001407A1 (en) 2011-06-30
KR101637387B1 (en) 2016-07-07
KR20100123899A (en) 2010-11-25
IL207720A0 (en) 2010-12-30
AR070797A1 (en) 2010-05-05
AU2009221327B2 (en) 2014-03-27
EA021904B1 (en) 2015-09-30
HUE027811T2 (en) 2016-11-28
US20130123257A1 (en) 2013-05-16
BRPI0908406B1 (en) 2019-04-09
CA2717718A1 (en) 2009-09-11
EP2247580A1 (en) 2010-11-10
IL207720A (en) 2014-12-31
WO2009109258A1 (en) 2009-09-11
CN101952258A (en) 2011-01-19

Similar Documents

Publication Publication Date Title
MX2010009576A (en) Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes.
TW200745004A (en) Novel compounds, their preparation and use
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2011011661A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750.
IN2012DN01233A (en)
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
UA83875C2 (en) Quinoline derivatives for use as mycobacterial inhibitors
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
PT1902037E (en) 2,4-diamino-pyrimidines used as aurora inhibitors
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
MY153258A (en) Pyrazinone derivatives and their use inthe threatment of lung diseases
EP2571876A4 (en) Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
MX2010009022A (en) 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use.
MY155695A (en) Quinoxalinedione derivatives
MX2010009922A (en) Pyridazinone glucokinase activators.
MX2010009575A (en) Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
MX2010005649A (en) Novel compounds as cannabinoid receptor ligands and uses thereof.
MX2009007713A (en) Pyridazine derivatives, processes for their preparation and their use as fungicides.
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof

Legal Events

Date Code Title Description
FG Grant or registration